UNSPSC 51413106: Fasudil hydrochloride

This classification denotes a protein kinase inhibitor with the molecular formula C14H17N3O2S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SQ04N8S7BR, chemically known as 5-(1,4-diazepan-1-sulfonyl)isoquinoline but more generally known as fasudil hydrochloride, which bears US NIH Compound Identifier 3547. European Medicines Agency schedules Fasudil hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21642.

Most nations, for tariff and trade purposes, schedule fasudil hydrochloride under HS 29350090 and SITC 51580. As of Q4 2014, FASUDIL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C1CC2CNCCC2C(C1)S(=O)(=O)N3CCCNCC3.CL.

UNSPSC 51413106 Fasudil hydrochloride, a Commodity code, nominally describes a single pharmaceutical agent, but the recent state and local opportunities tagged under it reflect broader emergency medical and pharmacy benefit procurement rather than this specific drug. State and local governments are soliciting advanced life support medications, generic pharmaceuticals, and pharmacy benefit management services under this code. The City of Tampa's Fire Rescue department is purchasing a mix of critical-care injectables (epinephrine, adenosine, labetalol, diltiazem) through competitive sealed bidding; the Texas Health and Human Services Commission is exploring direct-to-manufacturer prescription fulfillment models through a preliminary Request for Information; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) is establishing cooperative contracts for generic and OTC pharmaceuticals across multiple state and local jurisdictions. The issuing bodies span city fire departments, state health commissions, and multi-state cooperative purchasing alliances, reflecting diverse procurement vehicles and geographic scope.

Geographic activity concentrates in Florida, Texas, and Minnesota based on recent opportunities. The Tampa Fire Rescue bid (due April 8, 2026) sought four specific medication line items totaling approximately $40,000 with firm pricing, nine-month minimum expiration dating, and a one-year contract term with renewal options; the City designated the solicitation for Small Local Business Enterprise (SLBE) participation with a 5 percent bid discount. The Texas HHS Commission's RFI (response deadline April 3, 2026) targeted vendor experience with direct contracting and self-insured health plans outside traditional pharmacy benefit manager arrangements, signaling the state's interest in alternative fulfillment channels. MMCAP's RFP (due March 26, 2026) established a cooperative multi-award framework for generic pharmaceuticals distributed through three authorized wholesalers, with contract effectiveness July 1, 2026, requiring cGMP certification, Drug Supply Chain Security Act compliance, and demonstrated pricing flexibility. The code shows mixed decision relevance — fire rescue emergency supplies and cooperative generic pharmacy procurement are active, but the nominal Fasudil code attachment appears incidental to the broader pharmaceutical and medical-supply categories these jurisdictions are actually buying.